CSS
CRDL

Cubist Systematic Strategies’s Cardiol Therapeutics CRDL Stock Holding History

Cubist Systematic Strategies’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$26.8K Buy
+25,079
New +$30.4K ﹤0.01% 2886

Other funds holding CRDL

TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Cubist Systematic Strategies's CRDL Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Cardiol Therapeutics (CRDL) in Q3 2025: 25,079 shares worth $26.8K. The stake represents ﹤0.01% of the portfolio and ranks #2886 among its holdings.

48 funds tracked by Wall St. Rank hold CRDL as of Q3 2025.

  • Cubist Systematic Strategies held 25,079 shares of Cardiol Therapeutics worth $26.8K as of Q3 2025.
  • Cardiol Therapeutics was a new Cubist Systematic Strategies position in Q3 2025.
  • Cardiol Therapeutics made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2886 holding.
  • 48 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.